SCHEMBL29629632

SCHEMBL29629632

O=C(NO)c1cc(CCNc2nc3cc(Cl)c(Cl)cc3s2)on1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 14/20 0.53
▸ HDAC1 Q13547 9/20 0.53
▸ HDAC4 P56524 1/20 0.53
▸ HDAC7 Q8WUI4 1/20 0.53
▸ HDAC11 Q96DB2 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC9 Q9UKV0 1/20 0.53
▸ HDAC5 Q9UQL6 1/20 0.53
▸ NPY1R P25929 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.41
▸ HDAC3 O15379 3/20 0.39
▸ HDAC2 Q92769 3/20 0.39
▸ HDAC10 Q969S8 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20524145 1.00 HDAC6 (0.53) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL29629608 0.83 ALDH1A1 (0.43) NPY1RHSD17B10RAB9ANPC1KDM4E
SCHEMBL20524090 0.83 ALDH1A1 (0.43) NPY1RHSD17B10RAB9ANPC1KDM4E
SCHEMBL20524110 0.81 HDAC6 (0.56) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL29629614 0.81 HDAC6 (0.56) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524068 0.77 HDAC6 (0.56) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL29629611 0.74 HDAC6 (0.58) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524166 0.74 HDAC6 (0.58) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524141 0.73 HDAC6 (0.55) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL29629605 0.73 HDAC6 (0.55) HDAC6HDAC1HDAC4HDAC7HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 — — US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 — — US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 — — US claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 — — US disclosed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 — — US disclosed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 — — US disclosed
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-07-02 — — US disclosed
US-11472780-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY (US) 2022-10-18 — — US disclosed
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC3, HDAC1, HDAC4 HDAC6 10/4885HDAC1 2/4885HDAC4 3/4885
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885
US-11472780-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback